FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Dezentje

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Physiology

Living Beings

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
David A Dezentje; Dan E Arking; Madeline Kortenhorst; Kristen West; Aravinda Chakravarti; Scott E Kern
Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects.
Eike Gallmeier; Tomas Hucl; Jonathan R Brody; David A Dezentje; Khola Tahir; Jana Kasparkova; Viktor Brabec; Kurtis E Bachman; Scott E Kern
High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Steven C Cunningham; Eike Gallmeier; Tomas Hucl; David A Dezentje; Eric S Calhoun; Geppino Falco; Kotb Abdelmohsen; Myriam Gorospe; Scott E Kern
Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Dezentje (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: David A Dezentje; Dan E Arking; Madeline Kortenhorst; Kristen West; Aravinda Chakravarti; Scott E Kern
Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects.
Cancer biology & therapy 2009;8(4):347-55.
2007: Eike Gallmeier; Tomas Hucl; Jonathan R Brody; David A Dezentje; Khola Tahir; Jana Kasparkova; Viktor Brabec; Kurtis E Bachman; Scott E Kern
High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Cancer research 2007;67(5):2169-77.
2006: Steven C Cunningham; Eike Gallmeier; Tomas Hucl; David A Dezentje; Eric S Calhoun; Geppino Falco; Kotb Abdelmohsen; Myriam Gorospe; Scott E Kern
Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss.
Cancer research 2006;66(11):5560-4.
2006: Steven C Cunningham; Eike Gallmeier; Tomas Hucl; David A Dezentje; Kotb Abdelmohsen; Myriam Gorospe; Scott E Kern
Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
Cell cycle (Georgetown, Tex.) 2006;5(10):1090-3.
2005: Michiel S van der Heijden; Jonathan R Brody; David A Dezentje; Eike Gallmeier; Steven C Cunningham; Michael J Swartz; Angelo M DeMarzo; G Johan A Offerhaus; William H Isacoff; Ralph Hruban; Scott E Kern
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7508-15.
2004: Michiel S van der Heijden; Jonathan R Brody; Eike Gallmeier; Steven C Cunningham; David A Dezentje; Dong Shen; Ralph Hruban; Scott E Kern
Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
The American journal of pathology 2004;165(2):651-7.